Who
Brian Corvese
Director
Company insider
Files Form 4 as: Director, MiNK Therapeutics; Director, Agenus; Director, Performance Technologies.
In numbers
- Trades disclosed
- 68
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 7 Jun 2007
- Last trade
- 1 Sep 2026
- Last filed
- 2 Sep 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 2 Sep 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,633 at $10.95 | filing |
| 1 Sep 2026filed 2 Sep 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,633 at $10.95 | filing |
| 5 Aug 2026filed 11 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 5 Aug 2026filed 11 Aug 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 1 Jun 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,444 at $12.38 | filing |
| 1 Jun 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,444 at $12.38 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 24 Apr 2026filed 28 Apr 2026 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —210,000 at $0.00 | filing |
| 2 Mar 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,640 at $10.90 | filing |
| 2 Mar 2026filed 2 Jun 2026 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,640 at $10.90 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,395 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,395 at $0.00 | filing |
| 1 Dec 2025filed 3 Dec 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,612 at $11.09 | filing |
| 9 Sep 2025filed 11 Sep 2025 | INKT MiNK Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,225 at $0.00 | filing |
| 2 Sep 2025filed 3 Sep 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K1,290 at $13.86 | filing |
| 17 Jun 2025filed 20 Jun 2025 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —750 at $0.00 | filing |
| 17 Jun 2025filed 20 Jun 2025 | AGEN Agenusoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 2 Jun 2025filed 4 Jun 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K2,494 at $7.17 | filing |
| 3 Mar 2025filed 5 Mar 2025 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K2,033 at $8.79 | filing |
| 1 Dec 2024filed 3 Dec 2024 | INKT MiNK TherapeuticsBiotechnology | SEC FORM 4 Code A | $18K24,400 at $0.73 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.